Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 5Not yet recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Sarcoma 1Melanoma 1

Interventions

pembrolizumab 245Nivolumab 141Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 78atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 48Standard of Care 45Magnetic Resonance Spectroscopy 45Capecitabine 45Radiosurgery 44Cetuximab 44lenvatinib 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Transurethral Resection of Prostate × 1 year × Clear all
NCT03993678 2025-12-30

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Swiss Cancer Institute

Phase 1/2 Completed
28 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡